Athens Research is a technology company.
Athens Research has raised $2.0M across 1 funding round.
Athens Research has raised $2.0M in total across 1 funding round.
Athens Research has raised $2.0M in total across 1 funding round.
Athens Research's investors include Balderton Capital, Earl Grey Capital, Jude Gomila Rolling Fund, Y Combinator, Alexandre Scialom, Hanno Renner, Immad Akhund.
Athens Research & Technology (ART) is a biotechnology company specializing in the purification and supply of highly pure, highly active human proteins and polyclonal antisera for research, pharmaceutical, diagnostic, and calibrator applications.[1][2][4] Founded in 1986, it serves academic researchers, pharmaceutical scientists, diagnostic manufacturers, and calibrator producers by providing proteins from human plasma, erythrocytes, neutrophils, and other tissues, targeting studies in inflammation, autoimmune disease, cancer, coronary disease, Alzheimer's, and more.[2][4][5] With under 25 employees and revenue below $5 million, ART operates from a modern ISO 9001:2015-certified, BSL-2 facility in Athens, Georgia, emphasizing custom purification and bulk production capabilities.[1][6]
The company solves the challenge of obtaining research-grade, native proteins that are difficult to produce at scale, enabling advancements in life sciences through reliable reagents referenced in major publications worldwide.[2][4] Its growth includes limited funding (under $5 million across one round) and recognition like a Globe Award, highlighting its role as an early University of Georgia spinout.[1]
Athens Research & Technology was founded in 1986 by a group of University of Georgia researchers and local physicians as an early startup from UGA's Innovation Gateway program.[1] Emerging from academic expertise in protein purification, the company quickly focused on developing highly pure human proteins and polyclonal antisera, filling a niche for specialized research reagents.[2][5] Over nearly 40 years, ART has maintained steady operations, expanding its product catalog to include serine proteases, protease inhibitors, apolipoproteins, immunoglobulins, and others, while building a global customer base of researchers purchasing these for over 25 years.[2][4]
Pivotal moments include constructing an 11,000-square-foot BSL-2 facility in 2010 with cGMP capabilities and ISO 9001:2015 certification, enabling scalable production from micrograms to kilograms.[6] Media coverage, such as a 2012 Atlanta Journal Constitution feature, and awards like the Globe Award underscore its evolution from a university offshoot to a reliable biotech supplier.[1][6]
Athens Research & Technology rides the wave of advancing life sciences research, where demand for high-quality, native human proteins fuels drug discovery, diagnostics, and personalized medicine amid rising chronic disease burdens like cancer and Alzheimer's.[2][4] Its timing aligns with biotech's shift toward precision tools—post-2010 facility upgrades met growing needs for scalable, GMP-grade reagents as academic-to-commercial translation accelerated.[6] Market forces favoring ART include the expansion of biopharma R&D (e.g., inflammation and autoimmune therapies) and global research collaborations, where reliable suppliers like ART reduce barriers for under-resourced labs.[1][2]
By providing essential components for studies influencing coronary disease models and biotherapeutics, ART indirectly shapes the ecosystem, supporting university innovation pipelines (as a UGA success story) and enabling smaller firms to compete in protein-based assays.[1][4]
ART's niche dominance in protein purification positions it for steady growth as biotech R&D intensifies, potentially expanding via partnerships for novel therapeutics or AI-driven protein engineering tools. Trends like mRNA vaccines and organoid research will boost demand for its custom proteins, while facility expansions could capture more pharmaceutical outsourcing.[4][6] Its influence may evolve from reagent supplier to key enabler in accelerated drug development pipelines, sustaining its legacy as a quiet powerhouse in life sciences innovation.[1][2]
Athens Research has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $2.0M Seed | Balderton Capital, Earl Grey Capital, Jude Gomila Rolling Fund, Y Combinator, Alexandre Scialom, Hanno Renner, Immad Akhund |